MUC5AC profiling as a biomarker for predicting post-recurrence outcomes and guiding precision therapy in pancreatic ductal adenocarcinoma (PDA).

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.e16374
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MUC5AC profiling as a biomarker for predicting post-recurrence outcomes and guiding precision therapy in pancreatic ductal adenocarcinoma (PDA).

Ashwini Kumar Esnakula, Ravi Kumar Paluri, Lianbo Yu, Ashish Manne et al.
Journal of Clinical Oncology
Pancreatic and Hepatic Oncology Research
article

MUC5AC profiling as a biomarker for predicting post-recurrence outcomes and guiding precision therapy in pancreatic ductal adenocarcinoma (PDA).

Ashwini Kumar Esnakula, Ravi Kumar Paluri, Lianbo Yu, Ashish Manne, Wancai Yang, Kannan Thanikachalam
article en

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 43(16_suppl)
Roswell Park Comprehensive Cancer Center (US), Wake Forest University (US), The Ohio State University (US)
Openalex Percentile: Top 82%
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.